The FDA has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose programmed death ligand-1 (PD-L1) score is ≥1.
MARCH 10, 2025